The International Generic and Biosimilar medicines Association (IGBA), which represents global manufacturers of generic and biosimilar medicines, today announces the publication of its first peer-reviewed scientific paper on biosimilar medicines development: The Path Towards a Tailored Clinical Biosimilar Development (Biodrugs).
The International Generic and Biosimilar medicines Association (IGBA), which represents global manufacturers of generic and biosimilar medicines, today requests urgent action by all governments to designate all medicines as PRIORITY ESSENTIAL PRODUCTS, including all critical goods needed to manufacture them, so as to ensure that patients around the globe can continue to access the medicines they need during the COVID-19 pandemic.
The current operating model of medicines supply requires transparent global collaboration to provide access to medicines for patients around the world.
- COVID-19: Urgent call to governments - Air freight must reopen for critical medicines and supplies for their manufacture (23 March 2020)
- COVID-19: Critical to keep the supply chain of essential medicines manufacturing operating at full capacity (18 March 2020)
- Hanan Sboul takes over the position of IGBA Chair (January 2020)
- IGBA applauds long-awaited scientific harmonization process of bioequivalence studies (December 2019)
